Confidential Addiction Treatment for Healthcare Professionals: Alcohol, Opioids, and What Telehealth Changes

You already know the diagnostic criteria. You have counseled patients through this exact conversation. That clinical knowledge is not what is keeping you from care.

What keeps most physicians, nurses, pharmacists, and advanced practice clinicians out of treatment is a professional calculation, not a medical one: what happens to my license, my credentials, my hospital privileges, my standing among people I work beside every day. That calculation is not irrational. It is also, for a growing number of clinicians, based on a version of the rules that has materially changed in the past four years.

This article covers what the evidence and the regulators actually say about seeking care for alcohol use disorder (AUD) and opioid use disorder (OUD) as a licensed healthcare professional, where telehealth genuinely helps, and — just as important — where it is the wrong level of care.

How Common This Is Among People Who Do Your Job

Substance use disorders in healthcare professionals are frequently discussed as an opioid problem. In practice, alcohol is the far more common story across the workforce, and it is the one most easily normalized by shift culture.

• Physicians: In a national study of more than 7,000 U.S. physicians using the AMA Physician Masterfile, 12.9% of male physicians and 21.4% of female physicians met criteria for alcohol abuse or dependence. Misuse of prescription drugs and use of illicit drugs was comparatively rare (Oreskovich et al., American Journal on Addictions, 2015).
• Surgeons: A parallel study of American College of Surgeons members found point prevalence of alcohol abuse or dependence at 13.9% for male surgeons and 25.6% for female surgeons. Surgeons who reported a major medical error in the previous three months were significantly more likely to screen positive (Oreskovich et al., Archives of Surgery, 2012).
• Nurses: A retrospective review of 1,533 Texas nurses referred for impaired practice found opioids and alcohol as the two leading substances, with roughly a third of participants involving more than one substance. The most common referral reasons were diversion, impairment at work, and arrest — meaning most cases surfaced through a workplace event rather than through voluntary disclosure.

Access matters at the margins. Anesthesia, emergency medicine, and critical care carry documented workplace exposure to high-potency agents, and diversion is a real and specific risk in those settings. But focusing only on those specialties misses the larger picture: the most common presentation across nursing, medicine, pharmacy, and allied health is a professional whose drinking has quietly escalated over years, who is functioning, and who has told no one.

Why Healthcare Professionals Wait Longer Than Almost Anyone Else

The delay is consistent enough to be predictable, and it has identifiable causes:

• Fear of licensure consequences. The single most cited barrier. Clinicians assume that any disclosure — even of treatment sought voluntarily, with no impairment at work — triggers board action.
• Self-treatment and self-diagnosis. Prescribing knowledge and sample access make it possible to manage symptoms privately for a long time. Clinical expertise becomes a barrier to care rather than a route into it.
• Being recognized. Local treatment often means a waiting room in your own health system, a chart in an EHR your colleagues can access, and a pharmacy staffed by people you round with.
• Schedules that do not accommodate care. Nights, call, rotating shifts, and 12-hour blocks make standing weekday appointments genuinely difficult, not merely inconvenient.
• Professional identity. Moving from clinician to patient is a role reversal most training actively discourages.

The cost of that delay is measurable. When SUD surfaces through a diversion investigation or an impairment event rather than through voluntary care, the professional consequences are substantially worse — and the clinical picture is usually more advanced.

What has Actually Changed: Licensure, Credentialing, and Privacy

Four developments have shifted the landscape. None of them makes treatment consequence-free, and none of them substitutes for advice from a licensure attorney in your state. But collectively they mean the assumptions many clinicians are operating on are out of date.

1. Licensing boards are moving from “have you ever” to “are you impaired now”

The Federation of State Medical Boards has counseled that application questions must focus only on current impairment — not on illness, diagnosis, or prior treatment — in order to comply with the Americans with Disabilities Act. The American Medical Association, the American Osteopathic Association, and the Dr. Lorna Breen Heroes’ Foundation have pushed the same standard through the ALL IN: Wellbeing First for Healthcare coalition.

The progress is documented and verifiable. As of May 15, 2026, the Wellbeing First Champion Challenge had verified that 44 medical licensure boards, 11 pharmacy boards, 9 nursing boards, 8 dental boards, and 2 specialty boards had removed intrusive, stigmatizing mental health and substance use questions from their applications — covering nearly 2.8 million licensed health workers. On the employer side, 1,427 hospitals, freestanding emergency departments, and surgery centers, plus 1,965 urgent care centers and independent primary care clinics, had done the same with their credentialing applications.

Practical step: check whether your state board and your employer carry the Wellbeing First Champion badge before you assume the worst about a specific question on a specific form.

2. Treatment for Opioid Use Disorder is Protected Under the ADA

People receiving medication for opioid use disorder are generally considered to have a disability under the ADA, and the Department of Justice has enforced that position against licensing bodies directly.

In September 2022, DOJ entered a settlement agreement with the Indiana State Board of Nursing resolving claims that it violated Title II of the ADA. The Board had required nurses to discontinue prescribed medication for OUD as a condition of participating in the state nursing assistance program — the program often required to maintain or reinstate a license. Under the agreement, the Board must allow nurses to participate while taking medication prescribed as part of a medically necessary treatment plan, revise its written policies, and pay $70,000 in damages. Assistant Attorney General Kristen Clarke stated that requiring nurses to stop prescribed OUD medication as a condition of licensure violates the ADA.

3. SUD Treatment Records Carry Protections Beyond HIPAA

Federal regulations at 42 CFR Part 2 govern the confidentiality of substance use disorder patient records and impose consent requirements stricter than HIPAA alone. Part 2 records generally may not be used in civil, criminal, administrative, or legislative proceedings without patient consent or a court order.

The 2024 final rule modernizing Part 2 reached its compliance deadline on February 16, 2026, and HHS’ Office for Civil Rights has since launched a civil enforcement program, accepting complaints and treating noncompliance as an enforcement priority. In short: the confidentiality framework around SUD treatment is not only intact, it is now actively enforced by the same office that has enforced HIPAA for decades.

4. Monitoring Programs Offer a Non-Disciplinary, Non-Public Path

Most states operate a physician health program (PHP) for physicians and an alternative-to-discipline (ATD) program for nurses. As the National Council of State Boards of Nursing describes them, ATD programs let a nurse demonstrate to the board in a non-disciplinary and non-public manner that they can become and remain safe and sober while retaining their license. Self-referral, before a workplace event forces the issue, is generally the version of this process with the most favorable terms.

Important limit: this is general information, not legal advice. Reporting duties vary by state, profession, employer contract, and — critically — by whether there is current impairment, patient harm, or diversion. Confidential treatment is not immunity from professional obligations. If you are impaired at work or diverting medication, self-referral to your state PHP or ATD program is the path that protects both your patients and your career, and a licensure attorney should be involved early.

Where Telehealth Genuinely Helps

Telehealth does not change the pharmacology. What it changes is the friction — and for this population, friction is the primary barrier to entry.

Alcohol use disorder: medication is available, effective, and badly underused

Three medications are FDA-approved for AUD: naltrexone (oral daily or monthly extended-release injection), acamprosate, and disulfiram. None is a controlled substance. All can be prescribed by a primary care clinician, and all are appropriate to initiate in a standard telehealth visit for patients without complicating factors.

The National Institute on Alcohol Abuse and Alcoholism describes these medications as vastly underused, citing an analysis finding they were prescribed for only 1.6% of adults with past-year AUD. For a clinician who has watched colleagues struggle with the same gap in their own patients, the irony is uncomfortable and worth naming: the treatment you would recommend to a patient is available to you, from home, without a controlled substance in the equation.

Opioid use disorder: buprenorphine via telemedicine

DEA and HHS have issued a fourth temporary extension of telemedicine flexibilities for prescribing controlled medications, effective January 1, 2026 through December 31, 2026. Under these flexibilities, DEA-registered practitioners may prescribe Schedule II–V controlled medications via audio-video telemedicine without a prior in-person evaluation, and FDA-approved Schedule III–V medications for maintenance and withdrawal management of OUD — buprenorphine among them — may be prescribed via audio-only encounters, provided all other federal and state requirements are met.

Separately, a final rule expanding buprenorphine treatment via telemedicine encounters took effect December 31, 2025, creating a durable pathway with its own documentation and technology conditions. Permanent rules are anticipated, and the regulatory picture should be re-verified before you rely on it — but as of this writing, telehealth initiation of buprenorphine is squarely permitted.

The practical differences that matter for shift workers

• Appointments outside standard clinic hours, scheduled around call and rotating shifts.
• No waiting room in the building where you work, and no local check-in desk staffed by colleagues.
• Care delivered outside your own health system’s EHR, with Part 2 protections applying to the treatment record.
• Pharmacy of your choosing, including one outside your immediate professional circle.
• Continuity across relocations, locums assignments, and travel contracts, subject to state licensure of the treating clinician.

Where Telehealth is the Wrong Level of Care

A program worth trusting will tell you this at the evaluation rather than after you enroll. Virtual care is not appropriate as the sole modality when any of the following apply:

Situation	Why it needs in-person or higher-acuity care
Moderate-to-severe alcohol withdrawal risk	History of withdrawal seizures or delirium tremens, high sustained daily intake, or prior complicated withdrawal requires medically supervised detoxification. Unsupervised alcohol cessation can be fatal.
Current impairment at work	This is a patient safety issue with immediate reporting and removal-from-practice implications that a telehealth visit cannot resolve.
Active diversion from the workplace	Involves investigation, employer obligations, and often law enforcement. Requires coordinated legal and program guidance.
Severe co-occurring psychiatric illness or suicidality	Needs urgent in-person psychiatric assessment and, potentially, a higher level of care.
An existing board or employer monitoring agreement	The agreement may specify approved evaluators, in-person components, observed testing, or a designated treatment provider. Its terms control.
Injectable naltrexone or observed testing requirements	Requires an in-person site for administration or collection, coordinated alongside virtual visits.

For many clinicians, the realistic answer is hybrid: a virtual evaluation and medication management relationship, coordinated with in-person components where the clinical picture or a monitoring agreement requires them.

The Monitoring Evidence — and One Caveat Worth Understanding

Outcomes for healthcare professionals who engage with structured monitoring are among the strongest in addiction medicine. In a five-year longitudinal cohort study of 904 physicians consecutively admitted to 16 state physician health programs, 78.7% were licensed and working at five-year follow-up. Of the 647 physicians who completed treatment and resumed practice under supervision, alcohol or drug use was detected by urine testing in 19% across the full five years (McLellan, Skipper, Campbell & DuPont, BMJ, 2008).

Those numbers deserve accurate interpretation. They reflect five years of intensive, contingency-linked monitoring with frequent random testing and meaningful consequences — not a different underlying biology. They should not be generalized to unmonitored populations, and the study design has known limitations. What they do support is a specific and useful claim: sustained structure works, and healthcare professionals who engage early do well.

The medication tension

Many monitoring programs have historically been abstinence-based and have discouraged or restricted agonist therapy for OUD. That position is increasingly recognized as inconsistent with the evidence base for buprenorphine and methadone, and — as the Indiana settlement demonstrates — potentially inconsistent with the ADA when applied as a blanket condition of licensure.

If you are entering or already in a monitoring agreement, ask directly and get the answer in writing: does this program permit medication for opioid use disorder prescribed as part of a medically necessary treatment plan, and under what documentation conditions? Do not assume the answer either way based on the program’s reputation or its policy from several years ago. Policies have been revised, in some cases under federal pressure.

Practical First Steps

1. Screen yourself with a validated tool, honestly. AUDIT-C for alcohol takes under a minute. Score it as you would for a patient, not as you would for yourself.
2. Locate your state’s PHP or ATD program and read its terms now. NCSBN maintains a directory of alternative-to-discipline programs by jurisdiction; the Federation of State Physician Health Programs maintains the equivalent for physicians. Read the terms before you need them.
3. Understand self-referral versus mandated referral in your state. These are usually different processes with materially different consequences, and the distinction is the single most important thing to establish early.
4. Check whether your board and employer have removed intrusive questions. The Dr. Lorna Breen Heroes’ Foundation publishes the verified list.
5. Get a confidential clinical evaluation. An evaluation is not enrollment, and it is not a disclosure to your employer. It establishes what level of care you actually need — which, for a large share of clinicians, is outpatient medication management and structured follow-up.
6. If you have any withdrawal risk, do not taper alcohol on your own. This is the one item on this list where acting without medical supervision carries a mortality risk.

The evidence on this population is unusually clear. Healthcare professionals who engage with treatment do well — often better than the patients they treat. The variable that predicts outcome is not how far the illness has progressed. It is how early the person walks through the door.

Frequently Asked Questions

Sources and Further Reading

• American Medical Association — Issue Brief: Physician Health and Wellness; guidance on licensing and credentialing questions. https://www.ama-assn.org/system/files/issue-brief-physician-health-wellness.pdf
• Federation of State Medical Boards — Physician Wellness and Burnout: Report and Recommendations of the Workgroup on Physician Wellness and Burnout. https://www.fsmb.org/siteassets/advocacy/policies/policy-on-wellness-and-burnout.pdf
• Dr. Lorna Breen Heroes’ Foundation / ALL IN: Wellbeing First for Healthcare — Wellbeing First Champion Challenge, verified licensure and credentialing boards (data current as of May 15, 2026). https://drlornabreen.org/more-than-3-35-million-health-workers-now-practice-in-states-and-systems-that-support-their-mental-health/
• National Council of State Boards of Nursing — Alternative to Discipline Programs; Substance Use Disorder in Nursing resources. https://ncsbn.org/nursing-regulation/discipline/board-proceedings/alternative-to-discipline.page
• Federation of State Physician Health Programs — PHP Guidelines; Safety Considerations for Medication Treatment of Opioid Use Disorders in Monitored Health Professionals. https://fsphp.memberclicks.net/assets/MEMBERPORTAL/FSPHP%20Safety%20Considerations%20and%20Medication-Assisted%20Treatment%20for%20SUD%20among%20Physicians%20Monitored%20by%20PHPs%20August%202022.pdf
• U.S. Department of Justice — Settlement Agreement with the Indiana State Board of Nursing (September 1, 2022); Guidance on protections for people with opioid use disorder under the ADA (April 5, 2022). https://www.justice.gov/archives/opa/pr/justice-department-secures-settlement-agreement-indiana-state-nursing-board-addressing
• U.S. Department of Health and Human Services — Confidentiality of Substance Use Disorder Patient Records, 42 CFR Part 2; Office for Civil Rights enforcement program (February 2026). https://www.hhs.gov/press-room/hhs-announce-civil-enforcement-program-sud-patient-records.html
• Drug Enforcement Administration and HHS — Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications; Expansion of Buprenorphine Treatment via Telemedicine Encounter. https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled
• National Institute on Alcohol Abuse and Alcoholism — Core Resource on Alcohol: Recommend Evidence-Based Treatment — Know the Options. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol
• Oreskovich MR, Shanafelt T, Dyrbye LN, et al. The prevalence of substance use disorders in American physicians. Am J Addict. 2015;24(1):30-38. https://pubmed.ncbi.nlm.nih.gov/25823633/
• Oreskovich MR, Kaups KL, Balch CM, et al. Prevalence of alcohol use disorders among American surgeons. Arch Surg. 2012;147(2):168-174. https://pubmed.ncbi.nlm.nih.gov/22351913/
• McLellan AT, Skipper GS, Campbell M, DuPont RL. Five-year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ. 2008;337:a2038. https://pubmed.ncbi.nlm.nih.gov/18984632/

Medical and legal disclaimer: This article is for general educational purposes and does not constitute medical, legal, or licensure advice. Regulatory requirements described here — including DEA telemedicine flexibilities — are subject to change. Reporting obligations differ by state, profession, and circumstance. Consult a licensed clinician regarding your health and a licensure attorney regarding your professional obligations.